Global Female Sexual Dysfunction Treatment Market Size, Status and Forecast 2020-2026

Sexual dysfunction is difficulty experienced by an individual or a couple during any stage of a normal sexual activity, including physical pleasure, desire, preference, arousal or orgasm.
The increasing prevalence of chronic diseases is one of the key factors that will drive the growth of the market during the forecast period. Women suffering from chronic health conditions such as diabetes may also be diagnosed with sexual dysfunction. Clinical indications, including hypertension, obesity, metabolic syndrome, and atherogenic dyslipidemia, of chronic conditions such as diabetes, are the risk factors for sexual dysfunctions in women. The rising prevalence of chronic health conditions in women will increase the incidence of female sexual dysfunctions. This will provide considerable growth opportunities to market participants.

Mental health conditions such as depression are being recognized as critical health issues mostly among women. As a result, many pharmaceutical companies are releasing drugs and therapies to treat these conditions leading to an increase in the consumption of antidepressants, antipsychotics, and antiepileptics. Moreover, there is also an increase in the consumption of contraceptives. These drugs cause sexual dysfunctions in women.
Market Analysis and Insights: Global Female Sexual Dysfunction Treatment Market
In 2019, the global Female Sexual Dysfunction Treatment market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2021-2026.
Global Female Sexual Dysfunction Treatment Scope and Market Size
Female Sexual Dysfunction Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Female Sexual Dysfunction Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Female Sexual Dysfunction Treatment market is segmented into Non-hormonal Therapy, Hormonal Therapy, etc.
Segment by Application, the Female Sexual Dysfunction Treatment market is segmented into Sexual Desire Disorders, Sexual Arousal Disorders, Orgasm Disorders, Sexual Pain Disorders, Post-orgasmic Diseases, Pelvic Floor Dysfunction, Other, etc.
Regional and Country-level Analysis
The Female Sexual Dysfunction Treatment market is analysed and market size information is provided by regions (countries).
The key regions covered in the Female Sexual Dysfunction Treatment market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape

and Female Sexual Dysfunction Treatment Market Share Analysis
Female Sexual Dysfunction Treatment market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Female Sexual Dysfunction Treatment business, the date to enter into the Female Sexual Dysfunction Treatment market, Female Sexual Dysfunction Treatment product introduction, recent developments, etc.
The major vendors include AMAG Pharmaceuticals Inc., Duchesnay Inc., Emotional Brain BV, Novo Nordisk AS, Sprout Pharmaceuticals Inc., etc.

This report focuses on the global Female Sexual Dysfunction Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Female Sexual Dysfunction Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

AMAG Pharmaceuticals Inc.
Duchesnay Inc.
Emotional Brain BV
Novo Nordisk AS
Sprout Pharmaceuticals Inc.
...

Market segment by Type, the product can be split into

Non-hormonal Therapy
Hormonal Therapy

Market segment by Application, split into

Sexual Desire Disorders
Sexual Arousal Disorders
Orgasm Disorders
Sexual Pain Disorders
Post-orgasmic Diseases
Pelvic Floor Dysfunction
Other

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Female Sexual Dysfunction Treatment status, future forecast, growth opportunity, key market and key players.
To present the Female Sexual Dysfunction Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Female Sexual Dysfunction Treatment are as follows:
History Year: 2015-2019

Base Year:

2019

Estimated Year:

2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions